A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A.

Trial Profile

A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK0518 Versus KALETRA in HIV-Infected Patients Switched From a Stable KALETRA-Based Regimen - Study A.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Raltegravir (Primary) ; Antiretrovirals; Lopinavir/ritonavir
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWITCHMRK-1
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Jan 2010 Results were published in 'The Lancet'.
    • 17 Dec 2009 Patient numbers amended from 340 to 352 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top